Anti-CD22 CAR T Cells Lead to Remission in B-Cell ALL – Clinical Oncology News
Clinical Oncology News |
Anti-CD22 CAR T Cells Lead to Remission in B-Cell ALL
Clinical Oncology News All patients had received a previous hematopoietic cell transplant, 11 had received previous treatment with an anti-CD19 CAR T-cell therapy and five had received prior therapy with blinatumomab (Blincyto, Amgen). All 16 patients had CD22-positive ALL … |
